Elias Jabbour
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Elias Jabbour
Jun 21, 2024, 09:47 |
Blog
Blinatumomab alternating with LIC in older adults with newly diagnosed B-ALL - ALL Hub
ALL Hub shared a post on X: "CONGRESS | POSTER | EHA2024 | Elias Jabbour…
Jun 2, 2024, 22:16 |
Insight
ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
Clinical trial results suggest new treatment options could reduce need for stem cell transplants and…
May 19, 2024, 10:00 |
Blog
Hagop Kantarjian: A comprehensive review of ponatinib in CML and Ph+ ALL
Hagop Kantarjian, Leukaemia professor and Chair at MD Anderson Cancer Center, shared on X: "A comprehensive…
Feb 18, 2024, 15:51 |
Blog
Hagop Kantarjian: In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate
Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer…
Nov 6, 2023, 03:36 |
Drugs
Hagop Kantarjian: Inotuzumab is safe and effective for the eradication of MRD in patients with B-cell ALL, with a MRD negativity rate of 69%
Hagop Kantarjian, Chair of MD Anderson Cancer Center, shared a post on Twitter: Inotuzumab is…
All:
5
Posts:
1 - 100
Blending Science and Compassion: Exclusive Conversation with ASCO President-Elect Eric J. Small
OncoDaily at ASCO 2024: OncoDaily Party, Yvonne Award and much more
Tedros Adhanom Ghebreyesus received University of Nicosia’s Honorary Doctorate
Lisa A. Lacasse: A major milestone towards Congress passing the bipartisan MCED Act
July is Sarcoma Awareness Month
Facebook
RSS Feed
Twitter
Linkedin
Youtube